Executive Summary
Regeneron reported $14.3 billion in 2025 revenues, up modestly from 2024, as surging Dupixent collaboration profits offset a 42% decline in U.S. EYLEA sales driven by biosimilar competition and patient migration to EYLEA HD.
What happened
Regeneron's 2025 financial results reflect a portfolio in transition. Total revenues increased 1% to $14.3 billion, while net income grew 2% to $4.5 billion. The company recorded diluted earnings per share of $41.48, up from $38.34 in 2024. However, the revenue composition shifted significantly. Total net product sales recorded by Regeneron declined 17% to $6.3 billion, driven by a 42% drop in EYLEA U.S. sales to $2.7 billion. This decline stemmed from biosimilar competition following the May 2024 expiration of U.S. regulatory exclusivity, patient transition to EYLEA HD, and loss of market share to compounded bevacizumab due to patient affordability constraints. EYLEA HD sales grew to $1.6 billion, but the combined EYLEA franchise in the U.S. declined from $6.0 billion to $4.4 billion. Offsetting this, collaboration revenue surged 21% to $7.3 billion, led by Sanofi collaboration revenue of $5.9 billion (up $1.4 billion), primarily reflecting Regeneron's share of profits from Dupixent, which saw global sales reach $18.4 billion. Libtayo global sales rose 19% to $1.5 billion. Operating expenses increased 5% to $10.8 billion, with R&D expenses rising $718 million to $5.9 billion (including a $155 million charge for a priority review voucher) and SG&A declining $254 million to $2.7 billion (reflecting lower charitable contributions to a patient assistance fund). Operating cash flow strengthened to $5.0 billion.
Why it matters for investors
The results illustrate Regeneron's growing reliance on collaboration economics and highlight execution risk around the EYLEA franchise transition. The company's revenue mix shifted notably: Sanofi collaboration revenue (mostly Dupixent) grew from 32% to 41% of total revenues, while the combined EYLEA HD and EYLEA franchise declined from 42% to 31%. This means Regeneron is increasingly dependent on profit-sharing from a single partnered asset (Dupixent) rather than directly controlled product sales. While EYLEA HD adoption is progressing, it has not offset the biosimilar erosion of EYLEA, and additional biosimilar launches expected in H2 2026 pose further risk. The company maintains strong cash generation with $5.0 billion in operating cash flow and holds $18.9 billion in cash and securities. However, margin pressure is evident: gross margin on net product sales declined from 86% to 82%, driven by manufacturing investments and higher inventory write-offs. The increase in R&D spending reflects pipeline expansion, but the company received multiple Complete Response Letters from the FDA in 2025 due to third-party manufacturing issues, delaying approvals. Regeneron's business model is shifting toward collaboration-driven profits, which reduces direct control but provides capital efficiency.
Bullish points
Dupixent global sales surged 26% to $18.4 billion, driving Regeneron's share of collaboration profits up $1.3 billion to $5.2 billion, demonstrating the strength of this partnered franchise across multiple indications
Strong cash generation with $5.0 billion in operating cash flow (up from $4.4 billion) and $18.9 billion in total cash and securities, providing ample capital for R&D investment, share buybacks, and dividends
EYLEA HD U.S. sales grew to $1.6 billion and now represent 37% of the combined EYLEA HD/EYLEA U.S. franchise, with recent FDA approvals for RVO indication and every-4-week dosing potentially supporting further adoption
Libtayo global sales grew 19% to $1.5 billion, supported by both U.S. and rest-of-world expansion, adding diversification beyond the EYLEA and Dupixent franchises
Operating margin remained healthy at 25%, and the company initiated a quarterly dividend program while maintaining $1.5 billion in remaining share repurchase authorization
Bearish points
EYLEA U.S. sales collapsed 42% to $2.7 billion due to biosimilar competition, with one biosimilar launched in Q4 2024 and additional launches expected in H2 2026, creating ongoing erosion risk
Combined EYLEA HD and EYLEA U.S. sales declined $1.6 billion year-over-year, indicating EYLEA HD uptake has not offset biosimilar pressure; the franchise lost share to compounded bevacizumab due to patient affordability issues
Revenue concentration risk increased as Sanofi collaboration revenue (primarily Dupixent) grew to 41% of total revenues, up from 32%, reducing control and increasing dependence on a single partnered asset and collaboration relationship
The company received multiple FDA Complete Response Letters in 2025 (including for odronextamab and EYLEA HD pre-filled syringe) due to third-party fill/finish manufacturing issues, delaying approvals and highlighting supply chain vulnerabilities
Gross margin on net product sales declined from 86% to 82%, driven by manufacturing investments, higher inventory reserves, and Libtayo royalty amortization, pressuring profitability as the revenue mix shifts
Key highlights
Regeneron faces a critical transition as biosimilar competition erodes its historically dominant EYLEA franchise. While EYLEA HD is gaining traction, the combined U.S. franchise declined $1.6 billion in 2025, with further pressure expected from additional biosimilar launches in H2 2026. The company is compensating through strong growth in its Dupixent profit share (up $1.3 billion), but this increases revenue concentration and dependence on Sanofi. Regeneron holds 14.9% voting control through its Class A shares, with management and directors holding 17.3% of combined voting power. The company is investing heavily in R&D ($5.9 billion, up 14%) and capital expenditures (expected $1.1 billion to $1.3 billion in 2026), focusing on pipeline expansion and manufacturing capacity. However, recent FDA delays due to third-party manufacturing issues raise execution concerns. Regeneron's business model is shifting toward collaboration-driven economics, which provides capital efficiency but reduces direct control over key revenue drivers. The company continues to generate strong cash flow and maintains a solid balance sheet, but the next 12-18 months will be critical in determining whether EYLEA HD can stabilize the retinal franchise and whether the pipeline can deliver new growth drivers beyond Dupixent.
Management commentary
Management explicitly stated that the company is 'substantially dependent on the success of EYLEA HD, EYLEA, and Dupixent' and noted that 'our aggregate EYLEA HD and EYLEA net product sales in the United States represented 31% and 42% of our total revenues' for 2025 and 2024, respectively. The company acknowledged that 'EYLEA U.S. net product sales declined by 42% compared to the corresponding period in 2024 as a result of competitive pressures' and that 'biosimilar versions of EYLEA have been approved by the FDA, and one such product has launched in the United States.' Management also noted that 'EYLEA and/or EYLEA HD net product sales recorded by us are likely to continue to be negatively impacted by biosimilar competition in the United States, including competition from additional biosimilar versions of EYLEA expected to launch in the United States in the second half of 2026.' On Dupixent, the company stated that 'Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 41% and 32% of our total revenues' for 2025 and 2024, respectively. Management disclosed that 'we believe that our existing capital resources, borrowing availability under the Credit Facility, funds generated by anticipated product sales, and funding for reimbursement of research and development expenses that we are entitled to receive under our collaboration agreements, will enable us to meet our anticipated operating needs for the foreseeable future.'
What to watch next
Investors should monitor:
Timing and commercial impact of additional EYLEA biosimilar launches expected in H2 2026, and whether EYLEA HD adoption can accelerate to offset further erosion
FDA decision on the EYLEA HD pre-filled syringe application, which received a Complete Response Letter in October 2025 due to third-party fill/finish manufacturing issues
Trajectory of Dupixent global sales and Regeneron's profit share, given the company's increasing dependence on this collaboration for overall revenue and profit growth
Resolution of recent FDA Complete Response Letters (including for odronextamab) and whether manufacturing quality issues at third-party fill/finish sites are resolved
Gross margin trend on net product sales, which declined from 86% to 82%, and whether ongoing manufacturing investments stabilize or further compress margins
This summary is based solely on excerpts from the company's Form 10-K filing.
